Author(s): Tan VP, Wong BC
Abstract Share this page
Abstract Chemoprevention may form the cornerstone in the management of gastric adenocarcinoma of the future. Helicobacter pylori eradication and aspirin and/or nonsteroidal anti-inflammatory drug therapy have emerged as front-runner chemotherapeutic agents due to the putative pathogenic mechanisms that they address. Before a population-based chemopreventive strategy can be recommended on a large scale, randomized controlled trials with follow-up of more than 10 years of these 2 agents in populations at high gastric adenocarcinoma risk is urgently awaited. Copyright © 2013 Elsevier Inc. All rights reserved.
This article was published in Gastroenterol Clin North Am
and referenced in Journal of Clinical & Experimental Pathology